AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7722711 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole (high energy and high protein supplement: 163 kcals/682 kJ and 11.5 g protein per cup or 180 mL)
Number of subjects: 832
Study 7722711 — intervention group
Group type: COMPARATOR
Intervention: Fresco (low energy, no protein supplement: 59 kcals/247 kJ in 180 mL)
Number of subjects: 832
Study 7722711 — intervention group
Group type: COMPARATOR
Intervention: No supplement (immigrants, n = 144)
Number of subjects: 832
Study 1723468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine once daily
Number of subjects: 20
Study 1723468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine twice daily
Number of subjects: 20
Study 6342771 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU-VP (lomustine, vinblastine, and prednisone)
Number of subjects: 47
Study 6342771 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, procarbazine, and prednisone)
Number of subjects: 47
Study 6342771 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU-VP
Number of subjects: 47
Study 6342771 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 47
Study 6342771 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 47
Study 31752522 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acupoint Stimulation (TEAS)
Number of subjects: 52
Study 31752522 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS
Number of subjects: 52
Study 29913229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized peppermint essential oil for 15 minutes
Number of subjects: 106
Study 29913229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized eucalyptus essential oil for 15 minutes
Number of subjects: 106
Study 29913229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized rosemary essential oil for 15 minutes
Number of subjects: 106
Study 29913229 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 106
Study 26786780 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) (Ex-9) infusion
Number of subjects: 12
Study 26786780 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sitagliptin
Number of subjects: 12
Study 26786780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Ex-9-sitagliptin
Number of subjects: 12
Study 26786780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24329045 — intervention group
Group type: EXPERIMENTAL
Intervention: Renewal group (change in toothbrush every 4 weeks)
Number of subjects: 96
Study 24329045 — intervention group
Group type: COMPARATOR
Intervention: Non-renewal group (continuous use for 6 months)
Number of subjects: 96
Study 18347838 — intervention group
Group type: EXPERIMENTAL
Intervention: DdeI polymorphism (homozygote T/T allele)
Number of subjects: 104
Study 18347838 — intervention group
Group type: COMPARATOR
Intervention: MnlI and TaiI polymorphisms
Number of subjects: 104
Study 15581125 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused dimension on person in person-location pairs
Number of subjects: 0
Study 15581125 — intervention group
Group type: COMPARATOR
Intervention: Nonfocused dimension on location in person-location pairs
Number of subjects: 0
Study 11044759 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclectin (doxylamine-B6)
Number of subjects: 0
Study 11044759 — intervention group
Group type: COMPARATOR
Intervention: Control (other pharmacological agents)
Number of subjects: 0
Study 9048275 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 9048275 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 9048275 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study 9048275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8513519 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 40
Study 8513519 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular Meperidine (IM)
Number of subjects: 40
Study 2950914 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketoconazole shampoo
Number of subjects: 20
Study 2950914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30252149 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration betrixaban
Number of subjects: 7266
Study 30252149 — intervention group
Group type: COMPARATOR
Intervention: Shorter-duration enoxaparin
Number of subjects: 7266
Study 28968858 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% tapering TNFi
Number of subjects: 97
Study 28968858 — intervention group
Group type: EXPERIMENTAL
Intervention: 66% tapering TNFi
Number of subjects: 97
Study 28968858 — intervention group
Group type: COMPARATOR
Intervention: Control (constant TNFi)
Number of subjects: 97
Study 28968858 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% tapering TNFi (months 6-12)
Number of subjects: 97
Study 28968858 — intervention group
Group type: EXPERIMENTAL
Intervention: 66% tapering TNFi (months 6-12)
Number of subjects: 97
Study 26659791 — intervention group
Group type: EXPERIMENTAL
Intervention: sifalimumab (200-1200 mg) administered intravenously every 4 weeks for 52 weeks
Number of subjects: 298
Study 26659791 — intervention group
Group type: EXPERIMENTAL
Intervention: fixed dosing of sifalimumab
Number of subjects: 298
Study 24507941 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified antithrombin (5000 IU in three administrations)
Number of subjects: 60
Study 24507941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 22973178 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical pleth index (SPI) during propofol-remifentanil anaesthesia
Number of subjects: 80
Study 22973178 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical pleth index (SPI)
Number of subjects: 80
Study 19571155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon extract (Cinnulin PF) 250 mg, two times per day for 12 weeks
Number of subjects: 22
Study 19571155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 17341711 — intervention group
Group type: EXPERIMENTAL
Intervention: Atkins diet
Number of subjects: 311
Study 17341711 — intervention group
Group type: COMPARATOR
Intervention: Zone diet
Number of subjects: 311
Study 17341711 — intervention group
Group type: COMPARATOR
Intervention: LEARN diet
Number of subjects: 311
Study 17341711 — intervention group
Group type: COMPARATOR
Intervention: Ornish diet
Number of subjects: 311
Study 15059043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg once daily for 4 weeks
Number of subjects: 246
Study 15059043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg once daily for 10 days
Number of subjects: 246
Study 15059043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg once daily for 5 days
Number of subjects: 246
Study 15059043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole 40 mg (single-dose study)
Number of subjects: 246
Study 15059043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (first week) followed by oral esomeprazole
Number of subjects: 246
Study 11678744 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic dismembered pyeloplasty
Number of subjects: 50
Study 9141424 — intervention group
Group type: EXPERIMENTAL
Intervention: Banding ligation
Number of subjects: 71
Study 9141424 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 71
Study 7530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice a day until ANC was 1,000/microliters (Group I, n=29)
Number of subjects: 62
Study 7530677 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF from Day 2 until ANC was greater than 10,000/microliters (Group II, n=15)
Number of subjects: 62
Study 7530677 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Group III, n=18)
Number of subjects: 62
Study 7530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with G‐CSF prophylaxis (n=24)
Number of subjects: 62
Study 7530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin only (n=3)
Number of subjects: 62
Study 3652622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous frusemide (30 mg)
Number of subjects: 15
Study 3652622 — intervention group
Group type: COMPARATOR
Intervention: Oral indomethacin (100 mg)
Number of subjects: 15
Study 3652622 — intervention group
Group type: COMPARATOR
Intervention: Oral carbidopa (100 mg)
Number of subjects: 15
Study 31667685 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg/day)
Number of subjects: 66
Study 31667685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 29604502 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit encouragement (backchanneling, use of children's names)
Number of subjects: 143
Study 29604502 — intervention group
Group type: EXPERIMENTAL
Intervention: Putative confession (telling children that a suspect 'told me everything that happened and wants you to tell the truth')
Number of subjects: 143
Study 29604502 — intervention group
Group type: COMPARATOR
Intervention: Implicit encouragement
Number of subjects: 143
Study 29604502 — intervention group
Group type: COMPARATOR
Intervention: Putative confession
Number of subjects: 143
Study 27279471 — intervention group
Group type: COMPARATOR
Intervention: High-dose RO extract (HRE) 1800 mg/day
Number of subjects: 44
Study 27279471 — intervention group
Group type: COMPARATOR
Intervention: Low-dose RO extract (LRE) 900 mg/day
Number of subjects: 44
Study 24461574 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 14 mg
Number of subjects: 1169
Study 24461574 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide 7 mg
Number of subjects: 1169
Study 24461574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1169
Study 23733165 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar spray coagulation (Group A)
Number of subjects: 246
Study 23733165 — intervention group
Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA) application (Group B)
Number of subjects: 246
Study 20419973 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of verapamil every 14 days for 6 months
Number of subjects: 16
Study 17728193 — intervention group
Group type: EXPERIMENTAL
Intervention: Denufosol
Number of subjects: 89
Study 17728193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 16882525 — intervention group
Group type: EXPERIMENTAL
Intervention: Water treatment (active)
Number of subjects: 0
Study 16882525 — intervention group
Group type: COMPARATOR
Intervention: Sham (no water treatment)
Number of subjects: 0
Study 14594792 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based multicomponent intervention (dietary change, increased physical activity, classroom curriculum, family involvement)
Number of subjects: 1704
Study 14594792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1704
Study 11076816 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous prostacyclin infusion
Number of subjects: 10
Study 11076816 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 10
Study 8823067 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaving a message on answering machines
Number of subjects: 1323
Study 8823067 — intervention group
Group type: COMPARATOR
Intervention: No message left (Control)
Number of subjects: 1323
Study 1426656 — intervention group
Group type: COMPARATOR
Intervention: Immunomodulators
Number of subjects: 15
Study 3901764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepidil gel (0.5 mg)
Number of subjects: 59
Study 3901764 — intervention group
Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 59
Study 31215837 — intervention group
Group type: EXPERIMENTAL
Intervention: Online educational modules, community forum, communication with a lifestyle coach
Number of subjects: 151
Study 31215837 — intervention group
Group type: COMPARATOR
Intervention: Control group received internet links to CVD risk reduction information
Number of subjects: 151
Study 29526233 — intervention group
Group type: EXPERIMENTAL
Intervention: LooH with a spiritual context
Number of subjects: 3
Study 29526233 — intervention group
Group type: EXPERIMENTAL
Intervention: LooH without a spiritual context
Number of subjects: 3
Study 29526233 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 3
Study 26423685 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 35
Study 26423685 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib plus Candesartan
Number of subjects: 35
Study 26423685 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment after Axitinib
Number of subjects: 35
Study 26423685 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 35
Study 26423685 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (Control)
Number of subjects: 35
Study 24776785 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA intensity)
Number of subjects: 30
Study 24776785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2 mA intensity)
Number of subjects: 30
Study 24776785 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 22826137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 41
Study 22826137 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 41
Study 20303577 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroflowmetry biofeedback
Number of subjects: 86
Study 20303577 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training of the pelvic floor muscles
Number of subjects: 86
Study 20303577 — intervention group
Group type: EXPERIMENTAL
Intervention: Uroflowmetry biofeedback combined with biofeedback training of the pelvic floor muscles
Number of subjects: 86
Study 20303577 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 86
Study 18051616 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P parent training
Number of subjects: 280
Study 18051616 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 280
Study 15584064 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine 20 mg twice daily
Number of subjects: 77
Study 15584064 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.2 percent glyceryl trinitrate ointment
Number of subjects: 77
Study 11903078 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural PCA with bupivacaine 0.06% and sufentanil 1 microg x ml(‐1)
Number of subjects: 53
Study 11903078 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine 0.15 mg
Number of subjects: 53
Study 11903078 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural PCA
Number of subjects: 53
Study 11903078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 53
Study 9619712 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg subcutaneously every 4 weeks)
Number of subjects: 63
Study 9619712 — intervention group
Group type: COMPARATOR
Intervention: Goserelin plus mitomycin (14 mg/m2 i.v. every 6 weeks)
Number of subjects: 63
Study 7702998 — intervention group
Group type: EXPERIMENTAL
Intervention: + (R)-thalidomide
Number of subjects: 0
Study 7702998 — intervention group
Group type: EXPERIMENTAL
Intervention: - (S)-thalidomide
Number of subjects: 0
Study 7702998 — intervention group
Group type: COMPARATOR
Intervention: Racemate thalidomide
Number of subjects: 0
Study 2711155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin monotherapy
Number of subjects: 188
Study 2711155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin with hydrochlorothiazide/amiloride
Number of subjects: 188
Study 2711155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin with atenolol
Number of subjects: 188
Study 2711155 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin
Number of subjects: 188
Study 901134 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy intervention
Number of subjects: 0
Study 901134 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy intervention (second year participants)
Number of subjects: 0
Study 901134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 901134 — intervention group
Group type: EXPERIMENTAL
Intervention: Target symptoms
Number of subjects: 0
Study 31658111 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention in addition to Traditional Occupational Therapy
Number of subjects: 90
Study 31658111 — intervention group
Group type: COMPARATOR
Intervention: Traditional Occupational Therapy
Number of subjects: 90
Study 30007942 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb-encircling technique
Number of subjects: 16
Study 30007942 — intervention group
Group type: COMPARATOR
Intervention: Two-finger technique
Number of subjects: 16
Study 27965005 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamepad (experimental group)
Number of subjects: 42
Study 27965005 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy without biofeedback (control group)
Number of subjects: 42
Study 25434635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/day
Number of subjects: 940
Study 25434635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 940
Study 24241277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing consultations (nurse-delivered consulting home visits and follow-up telephone calls)
Number of subjects: 124
Study 24241277 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonequivalent control group)
Number of subjects: 124
Study 24241277 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing consultations
Number of subjects: 124
Study 24241277 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 21717984 — intervention group
Group type: EXPERIMENTAL
Intervention: High tibial osteotomy plus microfractures (Group A; n=20)
Number of subjects: 40
Study 21717984 — intervention group
Group type: COMPARATOR
Intervention: High tibial osteotomy alone (Group B; n=20)
Number of subjects: 40
Study 19400831 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% copper-zinc malonate-containing cream applied twice daily
Number of subjects: 21
Study 16707551 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus low-carbohydrate diet (Ex+Lo CHO)
Number of subjects: 9
Study 16707551 — intervention group
Group type: COMPARATOR
Intervention: Low-carbohydrate diet alone (Lo CHO)
Number of subjects: 9
Study 14750756 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/mL of adjunctive mitomycin C for 3 minutes
Number of subjects: 26
Study 14750756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMC)
Number of subjects: 26
Study 14750756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MMC and control)
Number of subjects: 26
Study 10693993 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (45/6.4 mg/kg/day in two divided doses for 10 days)
Number of subjects: 238
Study 10693993 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (10 mg/kg on Day 1, then 5 mg/kg daily on Days 2 through 5)
Number of subjects: 238
Study 9141110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic nebulizers (UltraNeb 99/100, UltraAIR, Aerosonic)
Number of subjects: 0
Study 9141110 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizers (Dura ProNeb, Pari‐LL, Sidestream, Marquest Acorn II, Hudson T Updraft II, Baxter MistyNeb, Pari‐LC, Pari IS‐2, disposable Sidestream)
Number of subjects: 0
Study 9141110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic devices
Number of subjects: 0
Study 9141110 — intervention group
Group type: COMPARATOR
Intervention: Jet nebulizers
Number of subjects: 0
Study 9141110 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet nebulizers and ultrasonic devices
Number of subjects: 0
Study 9114916 — intervention group
Group type: EXPERIMENTAL
Intervention: GR 32191 (20 mg and 40 mg, orally)
Number of subjects: 8
Study 9114916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3080882 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (1 to 8 mg per day)
Number of subjects: 10
Study 3080882 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 240 mg per day)
Number of subjects: 10
Study 3351815 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol treatment (6-month course)
Number of subjects: 73
Study 3351815 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no treatment)
Number of subjects: 73
Study 30731474 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide (290 μg)
Number of subjects: 29
Study 30731474 — intervention group
Group type: COMPARATOR
Intervention: PEG (historical control)
Number of subjects: 29
Study 30731474 — intervention group
Group type: EXPERIMENTAL
Intervention: Linaclotide
Number of subjects: 29
Study 30731474 — intervention group
Group type: COMPARATOR
Intervention: PEG
Number of subjects: 29
Study 28295221 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study 28295221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25462898 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0
Study 25462898 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin
Number of subjects: 0
Study 25462898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24592760 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 100
Study 24592760 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 100
Study 21504624 — intervention group
Group type: EXPERIMENTAL
Intervention: B/B Checker®
Number of subjects: 30
Study 18242811 — intervention group
Group type: EXPERIMENTAL
Intervention: E group (n=32)
Number of subjects: 92
Study 18242811 — intervention group
Group type: EXPERIMENTAL
Intervention: E-P group (n=29)
Number of subjects: 92
Study 18242811 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 92